Community Health Systems Inc (CYH) · Oct 28, 2026 · Earnings
Miss — Adjusted EPS -$0.48 vs approximately -$0.29 consensus; revenue $2.757B vs approximately $2.80B
Community Health Systems’ Q3 earnings missed on revenue and adjusted EPS, while weaker payer mix and acuity drove another 2026 guidance cut.
CHS is in a debt-reduction and portfolio-concentration phase: it has been selling lower-priority hospitals to focus on denser core markets and improve its balance sheet, while the broader hospital story depends on whether better same-store demand can overcome reimbursement and labor-cost pressure.
The quarter missed an already-low bar. Adjusted EPS was a $0.48 loss versus published consensus of roughly a $0.29 loss, while revenue was $2.757 billion versus approximately $2.80 billion expected. The filing also shows reported EPS of negative $0.63, down from positive $0.96 a year earlier, and Adjusted EBITDA of $280 million versus $376 million. (Financial Highlights)
| Metric | Q3 2026 | Comparison / expectation |
|---|---|---|
| Net operating revenue | $2.757B | $3.087B in Q3 2025; ~$2.80B consensus |
| Adjusted EPS | -$0.48 | -$0.29 consensus; $1.27 in Q3 2025 |
| Adjusted EBITDA | $280M | $376M in Q3 2025 |
| Same-store admissions | +2.2% | +0.7% for the first nine months |
| Same-store adjusted admissions | +3.6% | +1.9% for the first nine months |
| 2026 revenue guidance | $11.3B-$11.5B | Prior $11.4B-$11.6B |
| 2026 Adjusted EBITDA guidance | $1.225B-$1.275B | Prior $1.300B-$1.375B |
| 2026 diluted EPS guidance | -$1.70 to -$1.60 | Prior -$1.25 to -$1.10 |
| 2026 operating cash-flow guidance | $100M-$300M | Prior $300M-$500M |
The underlying problem is economics, not patient demand. Same-store admissions and adjusted admissions improved, and same-store revenue rose 3.8%, but unfavorable payer mix and lower patient acuity overwhelmed that volume progress. Management explicitly said payer mix and acuity “did not develop as expected,” while higher medical specialist fees and supplemental reimbursement costs also weighed on EBITDA. (Three Months Ended September 30, 2026; Selected Operating Data) 〔0〕
The guidance reset is the more important signal than the quarterly miss. CHS cut the midpoint of its 2026 Adjusted EBITDA outlook by about $87.5 million, reduced the revenue midpoint by $100 million, widened the expected full-year loss, and cut operating-cash-flow guidance by $200 million at the midpoint. The direction of pressure was already partly known after the July guidance reduction, but this filing shows the deterioration is continuing rather than stabilizing. The filing says the new projections update guidance issued July 22, 2026; the prior ranges were $11.4 billion-$11.6 billion of revenue and $1.3 billion-$1.375 billion of Adjusted EBITDA. 〔1〕
Cash flow improved sequentially but remains weak year to date. Third-quarter operating cash flow was $155 million versus $70 million a year earlier, yet the first nine months used $55 million compared with $277 million generated in the prior-year period. With $9.6 billion of long-term debt and only $155 million of cash at September 30, the lower full-year cash-flow outlook leaves less room for debt reduction after the divestiture program. (Cash Flows; Condensed Consolidated Balance Sheets)
The filing advances the portfolio cleanup but weakens the operating recovery story. CHS completed or announced ten hospital divestitures during 2026, reducing the reported footprint to 60 hospitals in the quarter and 59 as of October 28. That helps explain the consolidated revenue decline, but the same-store results show the remaining network is producing modest volume growth; the issue is that reimbursement mix and acuity are not converting that volume into earnings. (Other; Selected Operating Data) 〔2〕
Bottom line: This is a clear miss, and the bigger takeaway is a second outlook reset: demand is improving in the retained hospitals, but payer mix and acuity are preventing that progress from reaching cash generation or profitability. The debt-reduction strategy continues, but the operating recovery is moving more slowly and with less financial cushion than previously expected.
Q3 earnings call, October 29, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!